Fate Therapeutics stock adds two Q4 conference dates

Published on 10/07/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fate Therapeutics stock closed at USD 2.43 on October 5, 2026, while analysts set an average target of USD 5.90. Q2 revenue reached USD 2.08 million.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics stock (ISIN US31189P1021) closed at USD 2.43 on Nasdaq on October 5, 2026, while its market capitalization stood at USD 291.2 million on October 6. The clinical-stage biotechnology company has scheduled investor appearances for November and December, giving investors two near-term checkpoints for its cellular immunotherapy pipeline.

Two conferences set the calendar

According to GlobeNewswire on October 1, 2026, Fate Therapeutics will participate in the Jefferies Global Healthcare Conference beginning November 16 and the Piper Sandler Annual Healthcare Conference beginning December 1. The announced appearances put management communication ahead of the next major clinical and financial milestones.

The company develops off-the-shelf cellular therapies derived from induced pluripotent stem cells, with programs targeting cancer and autoimmune diseases. Its pipeline includes engineered T-cell and natural killer cell candidates, making clinical updates more important to the stock narrative than near-term commercial sales.

Losses still outweigh revenue

Fate Therapeutics reported second-quarter 2026 revenue of USD 2.08 million and a loss of USD 0.25 per share, according to MarketBeat. Revenue exceeded the cited consensus estimate of USD 1.94 million by USD 0.14 million, but the quarterly loss shows that the company remains dependent on clinical progress and financing capacity rather than product revenue.

The balance between pipeline progress and cash use is central to the investment case. Structured financial data show second-quarter operating cash flow of negative USD 23.434 million and cash and cash equivalents of USD 32.429 million at June 30, 2026, while net income was negative USD 30.159 million.

Analysts see a wide gap

MarketBeat reported on October 6, 2026, that eight analysts held a Hold consensus, comprising four Buy ratings, three Hold ratings and one Sell rating. The average target is USD 5.90, with published targets from USD 3.50 to USD 8.00, placing the average 142.8 percent above the October 5 Nasdaq close of USD 2.43.

The company also granted options for 62,900 shares at USD 2.30 and restricted stock units representing 72,700 shares on October 1, according to Fate Therapeutics. The awards are a personnel measure rather than a clinical catalyst, so the November and December conferences remain the clearer scheduled tests for investor communication.

FATE remains below its yearly high

Fate Therapeutics closed at USD 2.43 on Nasdaq on October 5, 2026, up 4.74 percent from the prior close. The 52-week range is USD 0.95 to USD 3.23, leaving the stock USD 0.80 below its yearly high.